Oviva Therapeutics is a pioneering startup that is developing first-of-its-kind therapeutics to enhance ovarian function and extend the healthspan of women. The company operates in the healthcare and biotechnology market, specifically focusing on women's health. The business model of Oviva Therapeutics revolves around the research, development, and commercialization of novel therapeutics that target ovarian function and longevity.

The company's primary clients are women who are experiencing or are at risk of age-related decline in ovarian function, which can lead to adverse health outcomes. Oviva Therapeutics aims to address this issue by developing innovative treatments that can extend the healthspan of women, thereby improving their overall health, well-being, and longevity.

The company generates revenue through the development and sale of these therapeutics. As the company's therapeutics are first-in-class, they have the potential to capture a significant market share in the women's health sector, providing a substantial revenue stream for the company.

Oviva Therapeutics is led by Daisy Robinton, PhD, who serves as the CEO and Co-Founder. The company is committed to not only developing effective therapeutics but also to elevating the broader conversation around women's health and building a coalition to drive this vision forward.

Keywords: Women's Health, Ovarian Function, Healthspan Extension, Therapeutics, Biotechnology, Healthcare, Age-Related Decline, Novel Treatments, Longevity, Oviva Therapeutics.